Resistance to thyroid hormone (RTH) is most often due to point mutations in the ␤-isoform of the thyroid hormone (TH) receptor (TR-␤). The majority of mutations involve the ligand-binding domain, where they block TH binding and receptor function on both stimulatory and inhibitory TH response elements. In contrast, a few mutations in the ligand-binding domain are reported to maintain TH binding and yet cause RTH in certain tissues. We introduced one such naturally occurring human RTH mutation (R429Q) into the germline of mice at the TR-␤ locus. R429Q knock-in (KI) mice demonstrated elevated serum TH and inappropriately normal thyroid-stimulating hormone (TSH) levels, consistent with hypothalamic-pituitary RTH. In contrast, 3 hepatic genes positively regulated by TH (Dio1, Gpd1, and Thrsp) were increased in R429Q KI animals. Mice were then rendered hypothyroid, followed by graded T 3 replacement. Hypothyroid R429Q KI mice displayed elevated TSH subunit mRNA levels, and T 3 treatment failed to normally suppress these levels. T3 treatment, however, stimulated pituitary Gh levels to a greater degree in R429Q KI than in control mice. Gsta, a hepatic gene negatively regulated by TH, was not suppressed in R429Q KI mice after T 3 treatment, but hepatic Dio1 and Thrsp mRNA levels increased in response to TH. Cardiac myosin heavy chain isoform gene expression also showed a specific defect in TH inhibition. In summary, the R429Q mutation is associated with selective impairment of TH-mediated gene repression, suggesting that the affected domain, necessary for TR homodimerization and corepressor binding, has a critical role in negative gene regulation by TH.
T hyroid-stimulating hormone (thyrotropin or TSH) is a heterodimeric glycoprotein consisting of 2 non-covalently linked protein subunits (TSH-␣ and TSH-␤), synthesized in the pituitary thyrotroph, which regulates the thyroid. TSH-releasing hormone (TRH) is synthesized in the paraventricular nucleus of the hypothalamus and released into the portal circulation, where it regulates the synthesis and glycosylation pattern (bioactivity) of pituitary TSH. The hypothalamic-pituitary-thyroid (HPT) axis is regulated by negative feedback involving thyroid hormones (THs) (T 4 and T 3 ), which are produced by the thyroid gland. The major negative regulator of TSH secretion is T 3 , which directly inhibits the transcription of the TSH-␣ and -␤ subunit genes (1) (2) (3) (4) (5) and TRH (6) (7) (8) .
TH action is mediated by different isoforms of the TH receptor (TR), which are members of the nuclear receptor superfamily of ligand-modulated transcription factors. Two genes, by alternative splicing and transcriptional start site utilization, express the known ligand-binding TR isoforms, TR-␣1, TR-␤1, TR-␤2, and TR-␤3. Negative regulation of the HPT axis is principally mediated by the ␤ isoform of the TR (9) (10) (11) (12) (13) .
On genes with a positive TH response element, TR interacts with corepressor proteins (CoRs) in the absence of ligand, and this complex mediates gene repression. In the presence of ligand, CoRs are released and replaced by a coactivator (CoA) complex that activates gene transcription (14, 15) . In contrast to genes positively regulated by TH, negatively regulated TH target genes show transcriptional activation in the absence of TH and repression in the presence of the ligand. Paradoxically, CoRs may increase transcription of the TSH subunit and TRH genes (16, 17) , whereas CoAs may have a role in ligand-dependent repression of negatively regulated genes. Both SRC-1 knockout mice and helix 12 mutant knock-in (KI) mice (which have TR that is unable to interact with coactivators) exhibit defective negative gene regulation by TH (18, 19) . The molecular mechanisms by which the same proteins that mediate gene activation on positively regulated genes also mediate gene repression on negatively regulated target genes are not well understood.
The syndrome of resistance to thyroid hormone (RTH), caused by mutations within the C terminus of TR-␤, is characterized by resistance to TH negative feedback at the pituitary and hypothalamus, with resulting TSH and TH elevation (20) (21) (22) (23) (24) . Acting in a dominant negative fashion, TR-␤ mutants cause RTH by interfering with the function of normal TRs (25) (26) (27) (28) . Although most RTH mutations cause generalized resistance to TH (GRTH), such that affected individuals are euthyroid or hypothyroid despite high circulating TH levels, some RTH mutations may be clinically associated with isolated central resistance to TH (CRTH), such that peripheral sensitivity to TH action is preserved (29, 30) .
In the present study, we hypothesized that the clinical syndrome of CRTH may result from differential effects of the TR-␤ mutation on positive vs. negative gene regulation. The molecular mechanism distinguishing GRTH and CRTH was probed through the generation of a KI mouse harboring a TR-␤ mutation associated with CRTH in humans. We find that a common CRTH mutation (R429Q) causes a selective defect in thyroid hormone repression while preserving TH stimulation. This is the first report of a mutant nuclear hormone receptor that dissociates ligand-dependent stimulation and inhibition in vivo. These results provide insight into the mechanisms by which TRs and associated cofactors may differentially regulate positive and negative target genes.
Results
Defective Interaction of the R429Q Mutant TR-␤ with Nuclear Corepressors. Codon 429 of TR-␤, located adjacent to the 3Ј end of the 9th heptad of the TR dimerization region, is conserved among related members of the nuclear hormone receptor superfamily. A point mutation in codon 429, converting an arginine to a glutamine (CGG to CAG) in 1 allele, has been described by our group as well as others as a naturally occurring mutation among patients with clinically apparent CRTH (31) (32) (33) (34) . We have previously demonstrated that the R429Q mutation does not impair the ability to bind ligand (32) . To test whether this mutant receptor could mediate CRTH, its binding properties were evaluated in gel mobility shift assays using in vitro transcribed and translated WT and mutant TR-␤ (supporting information Fig. S1 ). In the absence of retinoid X receptor (RXR), WT TR-␤ binds to DNA as a homodimer on a radiolabeled DR ϩ 4 element, whereas R429Q TR is homodimer deficient (Fig. S1 A) . In the presence of RXR, both WT and R429Q are able to form a heterodimer (Fig. S1B) , whereas we do not observe evidence for RXR homodimerization (data not shown). The TR-␤ homodimer forms a complex with the nuclear corepressor, NCoR, as we have previously demonstrated (35) . In contrast, the ability of the R429Q mutant receptor to complex with NCoR was significantly impaired, likely secondary to its deficient ability to homodimerize (Fig. S1C, Top) . In the presence of T 3 , WT TR-␤ binds coactivators via the AF-2 domain. Both WT and mutant TR-␤ bound a fragment of SRC-1, p160 coactivator, in the presence of T 3 (Fig. S1C, Bottom) .
To address the importance of the TR-␤ homodimer for receptor function in vivo, the R429Q mutation was introduced into the TR-␤ (Thrb) locus in exon 7 via homologous recombination in ES cells (Fig. S2 A) . Homologous recombination in ES cell clones was determined by Southern blot and PCR analysis (data not shown). The presence of the R429Q mutation was confirmed by subsequent sequencing of the cloned PCR product from ES cells (Fig. S2B) . Chimeric males were derived from 1 targeted ES cell clone and transmitted the mutation through crosses with C57BL/6 females; heterozygous mutant mice were interbred. The genotype of F1 and subsequent generations was identified by Southern blot (Fig. S2C ) and PCR analysis (Fig. S2D ). R429Q KI mice were born with no gross anatomic or functional abnormalities and were viable through adulthood. Both males and females displayed normal fertility.
Presence of the R429Q Mutation Did Not Significantly Affect TR mRNA
Isoform Expression in Mice. TR-␤ (Thrb) mRNA levels, as assessed using real-time quantitative PCR, were similar between WT and R429Q animals in both the pituitary and liver (Fig. S3 A and B) . Although TR-␣ (Thra) mRNA levels seemed to be somewhat higher in the pituitary and liver of R429Q compared with WT animals, this difference was not statistically significant ( Fig. S3  C and D) . Thus, the mutation did not significantly affect expression from either TR locus in central or peripheral tissues.
Central Axis in Mice Bearing the R429Q Mutation. The synthesis and secretion of THs are regulated by negative feedback control of the HPT axis. To elucidate the role of TR-␤ codon 429 in negative transcriptional regulation, we evaluated the axis in TR-␤ R429Q mutant animals. Serum total T 4 and T 3 levels were significantly elevated in TR-␤ (R429Q) KI mice, as shown in Fig.  1 A and B. TR-␤ R429Q/R429Q mice displayed T 3 and T 4 levels up to 3 to 4 times higher than in their WT littermates. Heterozygous animals displayed a 2-fold increase in T 4 and T 3 levels when compared with WT mice (Fig. 1 A and B) . Similar results were obtained in both male and female mice (data not shown).
Serum TSH levels were not suppressed in TR-␤ R429Q/WT and TR-␤ R429Q/R429Q mice despite elevated circulating TH concentrations, indicating that these mice have central resistance (Fig.  1C) . Basal levels of pituitary TSH-␤ (Tshb) subunit mRNA were significantly elevated in TR-␤ R429Q/R429Q mice and were not appropriately suppressed in heterozygous animals ( Fig. 1D) . A similar pattern was noted with ␣-GSU (Cga) subunit mRNA levels, which were not suppressed despite elevated TH levels in heterozygous and homozygous R429Q mutants.
Peripheral TH Action in Mice Bearing the R429Q Mutation. To investigate the effects of the R429Q mutant in peripheral tissues, we measured the expression of genes known to be transcriptionally regulated by TH in the liver. Type I 5Ј Deiodinase (Dio1), Spot 14 (Thrsp), and ␣-Glycerol Phosphate Dehydrogenase (Gpd1) are hepatic genes that are known to be positively regulated by TH. Dio1 and Gpd1 mRNA levels were significantly elevated in homozygous R429Q mutants, whereas Thrsp mRNA levels were increased in both TR-␤ R429Q/WT and TR-␤ R429Q/R429Q mice compared with WT controls (Fig. 2 A-C) . R429Q heterozygous and homozygous mutant mice also showed a significant reduction in body weight compared with WT animals (Fig. 2D) . Decreased weight, a major manifestation of thyrotoxicosis, has not been observed in mouse models of GRTH. Alpha-Glutathione-S-Transferase (Gsta) was studied as an example of a hepatic gene that is negatively regulated by TH. As was the case with Tshb, Gsta mRNA levels were significantly elevated in TR-␤ WT/R429Q and TR-␤ R429Q/R429Q mutant mice, indicating reduced responsiveness to TH inhibition of gene expression in the liver (Fig. 2E) . Extrahepatic peripheral genes known to be regulated by TH were also examined. Cardiac ␣-Myosin Heavy Chain (Myh6) and ␤-Myosin Heavy Chain (Myh7) are oppositely regulated by TH. Basal mRNA levels of Myh6, which are positively regulated by TH, were approximately 4-fold higher in the homozygous mutant mice compared with WT animals (Fig. 2F ). In contrast, mRNA levels of Myh7, which are negatively regulated by TH, were actually higher in TR-␤ R429Q/R429Q animals despite elevated TH levels (Fig. 2G ). Taken together, these data suggest that sensitivity to TH action is maintained on positively regulated genes but lost on negatively regulated genes in the liver and heart in the presence of the R429Q mutation. supplemented with propylthiouracil (PTU) and drinking water supplemented with methimazole (MMI), all animals presented with markedly elevated serum TSH levels and undetectable serum T 4 levels (data not shown). L-T 3 treatment was then administered by daily i.p. injections for 5 days at 3 escalating concentrations. At the end of the low-dose period, both TR-␤ R429Q/WT and TR-␤ R429Q/ R429Q mice exhibited significantly elevated TSH levels compared with WT animals (Fig. 3A) . In contrast to WT and TR-␤ R429Q/WT animals, serum TSH levels in TR-␤ R429Q/R429Q mice were not completely suppressed at the highest T 3 dose, indicating markedly reduced sensitivity to negative feedback by TH (Fig. 3A, Inset) . In the absence of ligand, Tshb mRNA levels were more than 2-fold higher in TR-␤ R429Q/R429Q animals than in WT littermates (Fig. 3B,  Inset) . After treatment at the highest T 3 dose, both Tshb and Cga mRNA levels failed to completely suppress in homozygous mutant mice, indicating a defect in negative regulation by TH (Fig. 3 B and  C) . In contrast, Gh mRNA levels in the setting of TH excess were higher in heterozygous and homozygous mutant animals than in WT controls, suggesting preserved and possibly enhanced TH action on a positively regulated pituitary gene (Fig. 3D) .
TH Regulation of Peripheral Genes in R429Q Mice. In the absence of ligand, Dio1 mRNA levels were 2-fold higher in R429Q mutant animals compared with controls (Fig. 4A, Inset) . In the presence of excess TH, TR-␤ R429Q/WT and TR-␤ R429Q/R429Q animals had somewhat lower levels of Dio1 mRNA compared with WT animals. Despite this, strong positive regulation of Dio1 by TH was maintained in mutant animals (Fig. 4A) . Thrsp expression was also examined, and again strong positive regulation was maintained in heterozygous and homozygous R429Q mice. In the presence of TH excess, Thrsp mRNA levels were found to be significantly increased in homozygous R429Q KI mice compared with WT controls (Fig.  4B) , suggesting enhanced positive regulation by TH in the presence of the mutation. The Gsta expression profile was similar to that of TSH subunit genes. Gsta mRNA levels in TR-␤ R429Q/R429Q mice were not suppressed even after treatment at the highest T 3 dose, indicating markedly impaired responsiveness to TH inhibition of gene expression (Fig. 4C) . The pattern of TH regulation of cardiac genes mirrored that of hepatic genes. Cardiac Myh6 mRNA levels increased appropriately in T 3 -treated TR-␤ R429Q/R429Q animals ( Fig. 4D) , whereas cardiac Myh7 mRNA levels failed to suppress in T 3 -treated heterozygous and homozygous mutants (Fig. 4E) . Given that TR-␣ is predominantly expressed in cardiac muscle, the lack of Myh7 mRNA suppression in this tissue in mice bearing the R429Q mutation suggests that this mutant TR-␤ mediates a strong dominant negative effect on negative gene regulation by TH.
Discussion
Two forms of RTH are clinically recognized: a generalized form (GRTH) and a central form (CRTH). However, the existence of CRTH as a distinct clinical entity remains controversial for 3 reasons: (i) the clinical characterization of affected patients is many times incomplete, (ii) unaffected and affected patients in the same family have been found to harbor the same TR-␤ mutation, and (iii) in vivo validation of CRTH in a model system is lacking.
We have successfully generated a transgenic mouse model of CRTH. Analysis of gene regulation in R429Q mice revealed that this TR-␤ mutation dissociates positive and negative gene regulation by TH rather than differentially affecting gene regulation on an anatomic basis (central vs. peripheral). Specifically, mice harboring the R429Q mutation demonstrate a selective defect in TH-mediated negative regulation of hepatic (Gsta), cardiac (Mhy7), and pituitary (Cga and Tshb) genes and preserved TH action on both peripheral and central genes that are positively regulated by TH. This is in contrast to other TR-␤ mutant mouse models of GRTH, all of which demonstrate defects in both positive and negative gene regulation by TH (Table 1) .
The mechanism by which a single TR mutation can exert dominant negative effect specifically on genes that are negatively regulated by TH remains unclear. An arginine at 429 is located in a highly conserved region within helix 11 of the ligand-binding domain. Crystallographic studies have demonstrated that this region contains a hydrophobic surface suitable for protein-protein interactions (36) , and mutations within this region have been demonstrated to selectively interfere with heterodimer or homodimer formation (32, (37) (38) (39) (40) . Consistent with prior studies, we found that the R429Q mutant TR is deficient in its ability to form a homodimer (32) . By contrast, all TR-␤ mutant mouse models of GRTH are homodimer sufficient ( Table 1 ), suggesting that the domain necessary for TR homodimerization has a role specific to negative gene regulation by TH. However, it is not clear that the TR homodimer is a relevant complex on TH negatively regulated genes. Alternatively, this mutation may disrupt a functional domain important for TH negative regulation, perhaps by blocking cofactor binding.
In contrast to GRTH TR-␤ mutants, R429Q TR cannot effectively recruit the nuclear corepressor NCoR (Table 1) . Astapova et al. (41) recently found that negative hepatic TH target genes were regulated normally in mice expressing in the liver a mutant NCoR protein (L-NCoR⌬ID) that cannot interact with the TR, suggesting that NCoR does not mediate negative gene regulation by TH. Others have reported that the R429Q mutant TR is impaired for silencing mediator of retinoid and thyroid receptors (SMRT) release in vitro (42), a functional property that has recently been reported in conjunction with deficient NCoR binding in another TR-␤ mutant (Mkar) discovered in a patient with predominantly central RTH (43) . However, it is unlikely that the observed specific defect in TH negative regulation with the R429Q mutant is due to defective SMRT release, given that (i) NCoR is the corepressor preferentially recruited by TR-␤ (44, 45) , (ii) we were unable to detect R429Q TR binding to SMRT in EMSA (data not shown), and (iii) Mkar had defective TH function on both positive and negative TH response elements.
Most TR-␤ mutants causing RTH are able to bind corepressor in the absence of T 3 but demonstrate impaired defective corepressor release and/or coactivator binding in response to T 3 (23, 24, 42, (46) (47) (48) (49) (50) (51) (52) (53) . The R429Q TR-␤ mutation does not impair ligand binding (32) , and in vitro characterization in the present study confirmed prior reports that this mutant receptor binds the coactivator SRC-1 in the presence of ligand. These binding characteristics are consis- tent with the finding of preserved sensitivity to TH on positively regulated genes in R429Q animals. R429Q animals demonstrated impaired ligand-independent repression of Dio1 transcription (Fig. 4A, Inset) , suggesting that ligand-independent repression on this gene in the liver is mediated by NCoR. Similar results were observed for Dio1 by Astapova et al. (41) in the setting of hepatic expression of L-NCoR⌬ID. That group furthermore reported deficient basal repression of hepatic Thrsp in mice expressing L-NCoR⌬ID. In contrast, we observed that ligandindependent repression of hepatic Thrsp was intact in the presence of R429Q, consistent with the results of prior in vitro studies using this mutant receptor (32) . The reason for this particular disparity is not clear but may relate to a differing degree to which the NCoR-TR interaction is deficient in our respective models. Alternately, it is possible that the deficient interaction of L-NCoR⌬ID with non-TR nuclear receptors (e.g., LXR) or other protein cofactors is contributing to the result they have observed.
The finding of elevated TSH subunit gene mRNA levels in hypothyroid R429Q mice compared with WT controls is consistent with our prior report using this mutant TR in transfection experiments (32) . The present study demonstrates that ligandindependent activation by TR can be increased in vivo. The mechanism for the enhanced ligand-independent activation of TSH subunit genes observed in the presence of R429Q mutant TR-␤ is not clear. Hollenberg et al. (54) cloned a truncated NCoR molecule (NCoRI) that lacks the repressing domains of full-length NCoR while retaining the interacting domains. NCoRI acted as a dominant negative inhibitor of endogenous NCoR in transfection experiments. Transfection of this NCoR inhibitor resulted in enhanced ligand-independent activation of the TRH gene by TR-␤1 and TR-␣ but not TR-␤2. If NCoR binding to the TR limits ligand-independent activation, then the inability of the R429 mutant to bind NCoR may help explain the enhanced ligandindependent activation seen in the presence of this mutation. This potential mechanism for enhanced ligand-independent activation is consistent with the finding of impaired ligand-independent activation in mice with pituitary-specific expression of ⌬337T, a GRTH mutant TR that constitutively binds to NCoR (55) . Consistent with our findings with liver Gsta, Astapova et al. (41) recently found that ligand-independent activation of hepatic TH target genes did not seem to be significantly affected by expression of L-NCoR⌬ID. It is thus possible that NCoR has a gene-or tissue-specific role in modulating ligand-independent activity on negatively regulated TH target genes.
Although CRTH is sometimes referred to as pituitary RTH (PRTH), we have in the past proposed that CRTH is a more appropriate term because isolated pituitary RTH is unable to elevate TH levels in mice (55) . However, like PRTH, CRTH seems to be a misnomer. Our present findings suggest that the clinical syndrome of CRTH is caused not by central resistance per se but rather by resistance specifically to negative gene regulation by TH. Genes that are negatively and positively regulated by TH exist in both central and peripheral tissues. Mutant TR-␤ effects on central negative (TSH subunit) genes can be easily evaluated with blood tests, whereas similar defects in the negative regulation of peripheral genes, such as Gsta, cannot be measured. Moreover, intact positive regulation in the setting of elevated TH levels may have clinically apparent effects on certain peripheral positive genes, such as cardiac Myh6, in tandem with clinically silent effects on central positive genes, such as Gh.
In addition to intact sensitivity to TH on positively regulated genes, R429Q TR-␤ mutant animals demonstrate weight loss consistent with thyrotoxicosis, a finding that has not been previously reported in mouse models of RTH. In contrast, the clinical finding of thyrotoxicosis has been inconsistently reported in humans harboring mutations associated with CRTH. The absence of a thyrotoxic phenotype in some patients carrying this mutation suggests that differences in background genetics, absent in inbred mouse strains, serve as important modifiers of TH action in humans. Given the findings in the present study, patients bearing the R429Q mutation, and perhaps other mutations that affect receptor homodimer formation or function, should be extensively evaluated for signs of peripheral thyrotoxicosis. On the basis of clinical studies, a reduction in TH levels may be indicated in these patients In summary, the R429Q TR-␤ mutation, which is associated with the clinical syndrome of CRTH, dissociates positive and negative gene regulation by TH in vivo. The ability to dissociate these pathways in vivo with a single TR-␤ mutation indicates that the TR contains a distinct domain that mediates TH inhibition. Further studies will be required to determine the specific mechanism by which a mutation affecting this region, which is critical for TR homodimer formation and corepressor binding, results in selective disruption of T 3 -mediated gene repression.
Materials and Methods
Plasmid Construction and Gel Mobility Shift Assay. The construction of pSG5 expression vector containing either full-length human TR␤2WT or TR␤R429Q was previously described (32) . Full-length human RXR␥, a PCR product ranging from amino acids 484 to 715 encoding the nuclear receptor binding domain of mouse steroid receptor coactivator 1 (SRC1-NBD1) (56) , and mouse cDNA encoding amino acids 1890 to 2326 of NCoR1, which contains the nuclear hormone receptor interaction domains (44) of NCOR1 (NCoR-ID), were inserted in pSG5 vector. Full-length protein for TR␤2WT and TR␤R429Q, SRC1-NBD1, NCoR-ID, and RXR␥ were in vitro generated in rabbit reticulocyte lysates (TNT T7 Quick Coupled Transcription/Translation System Kit; Promega). Interactions were tested on a 32 P-labeled DR ϩ 4 element, as described previously (49) . For each incubation reaction, the volume of in vitro translated protein used was 5 L for TR␤WT, TR␤R429Q, SRC1-NBD1, and NCoR-ID and 1 L for RXR␥. In some reactions T3 was added at concentration of 100 nM.
Generation of R429Q Mutant KI Mice. The targeting construct (Fig. S2 A) was electroporated into 129 ES cells, and G418 neomycin-resistant colonies were isolated and expanded. ES cells electroporated with the targeting vector were screened by Southern blot analysis using a probe external to the targeting vector (Fig. S2 A) and PCR analysis. One ES cell clone containing the targeting event was identified and was then injected into C57BL/6 blastocysts to generate chimeric mice. Chimeric mice were bred with C57BL/6 female mice to generate heterozygous and homozygous mice. Genotyping of tail DNA from R429Q mutant KI animals was performed by Southern blot and mismatch PCR analysis using the following primers: 5Ј Match: GATGAAGGTGACAGACCTGCG; 5Ј Mismatch: GAT-GAAGGTGACAGATCTGCA; and 3Ј Out: TGGATATTCCTGCACATTCCA.
Mice were maintained under 12-h light/12-h dark cycles (changes at 6 a.m. and 6 p.m.). All mice used in these experiments were of the same mixed background strain (129/C57BL/6), and WT animals were littermate controls. All animal experiments were performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at the Johns Hopkins University.
Serum TH and TSH Measurements. Serum TH levels were measured by an ELISA kit (total T3 and T4) from Alpha Diagnostic International. Mouse serum TSH levels were measured by a kit from Millipore (Rat Pituitary Panel Multiplex Assay, Luminex).
TH deficiency was induced in approximately 12-14-week-old mice in each of 3 groups-WT (TR-␤ WT/WT ), heterozygous (TR-␤ R429Q/WT ), and homozygous (TR-␤ R429Q/R429Q )-with a low-iodine diet containing 0.15% PTU (LoI/PTU; Harlan Tekland) and 0.05% MMI (Sigma) in water. After 5 weeks, animals received either vehicle or daily i.p. injections of a low (0.2 g per 100 g body weight per day), medium (0.5 g per 100 g body weight per day), or high (1.0 g per 100 g body weight per day) dose of L-T3 (Sigma) for 5 days each. The LoI/PTU diet and MMI in water were given throughout the L-T3 treatment period. The animals were killed 24 h after the last injection of L-T3.
RNA Analysis. Total RNA was extracted by standard methodology (TRIzol Reagent; Life Technologies, Invitrogen). RT was carried out on 1 g of total RNA for all tissues using the Access RT-PCR system (Promega). Real-time RT-PCR analyses were performed in a fluorescent temperature cycler (MyiQ Single-Color RealTime PCR Detection System; Bio-Rad) according to the recommendations of the manufacturer. Briefly, after initial denaturation at 50°C for 2 min and 95°C for 10 min, reactions were cycled 40 times using the following parameters for all genes studied: 95°C for 15 s, 60°C for 30 s, and 72°C for 30s. SYBR Green I fluorescence was detected at the end of each cycle to monitor the amount of PCR product formed during that cycle. All primers used for the amplification of cDNAs of interest were synthesized by Integrated DNA Technologies and are listed in Table S1 . Relative mRNA levels (2⌬Ct) were determined by comparing the PCR cycle threshold between groups. The purity of the PCR products was checked by analysis of the melting curves. Each sample was measured in duplicate, and each experiment was repeated at least 3 times. All results are expressed considering WT expression as 100%. The housekeeping gene used was 36B4.
Statistical Analysis. Data are reported as means Ϯ SEM. One-way ANOVA followed by Student-Newman-Keuls multiple comparisons test was used for assessment of significance when comparisons were made within the same genotype. Two-way ANOVA was used when mice of different genotypes and treatment were compared (GraphPad Prism; GraphPad Software). Differences were considered to be significant at P Ͻ 0.05.
